On January 17, 2019, the Federal Court of Appeal heard the Attorney General of Canada's appeal from a judicial review that quashed a Board decision that it has jurisdiction over Galderma's DIFFERIN (0.1% adapalene). Our report on the Federal Court decision, 2017 FC 1023, is found here. Innovative Medicines Canada intervened in the appeal. The Federal Court of Appeal reserved judgment.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
